Pharmacovigilance is organised at European or global level. Yet patient safety remains inherently local. Adverse events are reported locally, national authorities in BeNeLux are imposing specific requirements, and safety communications need to reach healthcare professionals and patients in the right language and through the appropriate channels.
This is where a Local Contact Person for Pharmacovigilance (LCP) plays an important role. Acting as the local link between the organisation, its EU Qualified Person for Pharmacovigilance (QPPV), local stakeholders and competent authorities, the LCP helps translate a central pharmacovigilance system into effective local practice.
Why Is Local Pharmacovigilance Support Important?
For pharmaceutical companies operating across multiple European markets, centralisation brings clear advantages. Processes such as case management, signal detection, aggregate reporting and maintenance of the Pharmacovigilance System Master File (PSMF) can often be managed efficiently at regional or global level.
However, centralisation does not eliminate the need for local knowledge and oversight.
Belgium, the Netherlands and Luxembourg operate within the European pharmacovigilance framework, but local interfaces, healthcare environments and national requirements still need to be understood and managed appropriately.
An effective local pharmacovigilance organisation therefore connects two perspectives:
The LCP provides this bridge.
What Does an LCP Do?
The exact responsibilities of an LCP depend on the organisation, product portfolio and applicable national requirements.
Typically, local PV support includes:
The purpose is not to duplicate the central PV organisation. Instead, the LCP helps ensure that local activities are properly integrated into the global PV system.
One Regional Approach, Three Local Markets
The BeNeLux offers an interesting environment for pharmaceutical companies. Belgium, the Netherlands and Luxembourg are closely connected geographically and commercially, making a regional approach attractive.
From a pharmacovigilance perspective, however, a BeNeLux model still needs to take account of the individual national environments.
A well-organised regional LCP model can therefore provide an efficient solution: one coordinated approach combined with the necessary knowledge of each local market.
For companies without an extensive local PV infrastructure, outsourcing this role can also provide continuity and access to local expertise without having to establish a separate PV organisation in every country.
Inspection Readiness Starts Before the Inspection
Local PV activities also need to be properly documented and integrated into the company’s quality system.
Clear responsibilities, appropriate procedures, training, documented oversight and functioning interfaces between local and global teams are therefore essential.
This becomes particularly visible during an audit or PV inspection. A company should be able to demonstrate not only how its PV system is designed, but also how it operates at local level in practice.
Having an experienced local contact who understands both the regulatory environment and the company’s PV system can make an important difference.
Local Presence, Global Connection
Pharmacovigilance may be increasingly globalised, but effective patient safety depends on what happens locally.
A strong LCP model helps ensure that local safety information is captured, local requirements are understood and local actions remain connected to the wider PV system.
At Q-support, we can provide pharmaceutical companies with an experienced Local Contact Person for Pharmacovigilance (LCP) across the BeNeLux, acting as the link between local activities and the wider European or global PV organisation. Our focus is pragmatic: understanding your organisation, integrating into your existing PV system and ensuring that local responsibilities are managed effectively.
Because in pharmacovigilance, being globally compliant also means being locally prepared.
By Liesbeth De Clercq